Pascal Deschatelets insider trades: Apellis Pharmaceuticals (APLS) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Pascal reports to the SEC
Open-market buys and sales
40 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 22, 2026 | APLS | ↓ Sell | 5,928 | $21.77 | $129K | Direct | Jan 23, 2026 (1d) |
| Jan 20, 2026 | APLS | ↓ Sell | 909 | $19.79 | $18K | Direct | Jan 21, 2026 (1d) |
| Jan 13, 2026 | APLS | ↓ Sell | 2,277 | $22.19 | $51K | Direct | Jan 15, 2026 (2d) |
| Jan 29, 2025 | APLS | ↓ Sell | 826 | $29.52 | $24K | Direct | Jan 30, 2025 (1d) |
| Jan 22, 2025 | APLS | ↓ Sell | 3,948 | $30.43 | $120K | Direct | Jan 23, 2025 (1d) |
| Jan 17, 2025 | APLS | ↓ Sell | 750 | $29.96 | $22K | Direct | Jan 21, 2025 (4d) |
| Jan 13, 2025 | APLS | ↓ Sell | 2,288 | $28.70 | $66K | Direct | Jan 14, 2025 (1d) |
| May 8, 2024 | APLS | ↓ Sell | 78,907 | $42.35 | $3.3M | Direct | May 9, 2024 (1d) |
| Apr 8, 2024 | APLS | ↓ Sell | 69,107 | $54.17 | $3.7M | Direct | Apr 9, 2024 (1d) |
| Mar 8, 2024 | APLS | ↓ Sell | 69,107 | $62.19 | $4.3M | Direct | Mar 11, 2024 (3d) |
| Feb 12, 2024 | APLS | ↓ Sell | 1,148 | $67.77 | $78K | Direct | Feb 13, 2024 (1d) |
| Jan 29, 2024 | APLS | ↓ Sell | 874 | $64.14 | $56K | Direct | Jan 31, 2024 (2d) |
| Jan 22, 2024 | APLS | ↓ Sell | 3,913 | $65.00 | $254K | Direct | Jan 23, 2024 (1d) |
| Jan 16, 2024 | APLS | ↓ Sell | 1,632 | $66.81 | $109K | Direct | Jan 17, 2024 (1d) |
| Nov 8, 2023 | APLS | ↓ Sell | 12,000 | $47.27 | $567K | Direct | Nov 9, 2023 (1d) |
| Oct 9, 2023 | APLS | ↓ Sell | 12,000 | $40.38 | $485K | Direct | Oct 10, 2023 (1d) |
| Sep 8, 2023 | APLS | ↓ Sell | 12,000 | $42.87 | $514K | Direct | Sep 11, 2023 (3d) |
| Aug 8, 2023 | APLS | ↓ Sell | 12,000 | $23.66 | $284K | Direct | Aug 9, 2023 (1d) |
| Jul 10, 2023 | APLS | ↓ Sell | 12,000 | $84.55 | $1.0M | Direct | Jul 11, 2023 (1d) |
| Jun 8, 2023 | APLS | ↓ Sell | 12,000 | $91.35 | $1.1M | Direct | Jun 9, 2023 (1d) |
| May 8, 2023 | APLS | ↓ Sell | 12,000 | $92.39 | $1.1M | Direct | May 9, 2023 (1d) |
| Apr 10, 2023 | APLS | ↓ Sell | 12,000 | $78.21 | $939K | Direct | Apr 11, 2023 (1d) |
| Mar 8, 2023 | APLS | ↓ Sell | 12,000 | $63.79 | $765K | Direct | Mar 10, 2023 (2d) |
| Feb 8, 2023 | APLS | ↓ Sell | 12,000 | $54.45 | $653K | Direct | Feb 10, 2023 (2d) |
| Jan 9, 2023 | APLS | ↓ Sell | 12,000 | $46.08 | $553K | Direct | Jan 10, 2023 (1d) |
| Dec 8, 2022 | APLS | ↓ Sell | 12,000 | $47.50 | $570K | Direct | Dec 12, 2022 (4d) |
| Nov 8, 2022 | APLS | ↓ Sell | 12,000 | $46.47 | $558K | Direct | Nov 10, 2022 (2d) |
| Oct 10, 2022 | APLS | ↓ Sell | 12,000 | $57.50 | $690K | Direct | Oct 11, 2022 (1d) |
| Sep 8, 2022 | APLS | ↓ Sell | 12,000 | $63.98 | $768K | Direct | Sep 12, 2022 (4d) |
| Aug 8, 2022 | APLS | ↓ Sell | 12,000 | $62.50 | $750K | Direct | Aug 9, 2022 (1d) |
| Jul 8, 2022 | APLS | ↓ Sell | 12,000 | $47.95 | $575K | Direct | Jul 12, 2022 (4d) |
| Jun 8, 2022 | APLS | ↓ Sell | 12,000 | $44.09 | $529K | Direct | Jun 9, 2022 (1d) |
| Apr 29, 2022 | APLS | ↓ Sell | 4,000 | $44.43 | $178K | Direct | May 2, 2022 (3d) |
| Jun 24, 2021 | APLS | ↓ Sell | 6,250 | $65.61 | $410K | Direct | Jun 25, 2021 (1d) |
| May 24, 2021 | APLS | ↓ Sell | 6,250 | $47.40 | $296K | Direct | May 25, 2021 (1d) |
| Apr 23, 2021 | APLS | ↓ Sell | 6,250 | $46.13 | $288K | Direct | Apr 26, 2021 (3d) |
| Mar 10, 2021 | APLS | ↓ Sell | 6,250 | $50.74 | $317K | Direct | Mar 11, 2021 (1d) |
| Feb 13, 2020 | APLS | ↓ Sell | 107,473 | $41.86 | $4.5M | Direct | Feb 14, 2020 (1d) |
| Sep 25, 2019 | APLS | ↓ Sell | 21,541 | $25.26 | $544K | Direct | Sep 26, 2019 (1d) |
| Sep 24, 2019 | APLS | ↓ Sell | 42,460 | $24.82 | $1.1M | Direct | Sep 25, 2019 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other APLS insiders
Open-market trades in the last 12 months
About Pascal Deschatelets's insider trades
Pascal Deschatelets is Chief Scientific Officer at Apellis Pharmaceuticals (APLS). Since Sep 24, 2019, Pascal has reported no open-market purchases and 40 sales worth $32.3M on SEC Form 4. In the last 12 months: 3 sales ($198K).
Their filings also include option exercises (33 filings), grants and awards (12 filings), shares withheld for taxes (7 filings), other transactions (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every APLS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.